Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis
Abstract:Shibata-Hamaguchi A, Samuraki M, Furui E, Iwasa K, Yoshikawa H, Hayashi S, Yamada M. Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis.
Acta Neurol Scand 2007: 116: 406–408.
© 2007 The Authors Journal compilation © 2007 Blackwell Munksgaard.
Anti-muscle-specific receptor tyrosine kinase (MuSK) antibody-positive myasthenia gravis (MG) patients show various responses to conventional immunosuppressive treatment and some patients are resistant to these therapies. We report a 50-year-old Japanese man with anti-MuSK antibody-positive MG, who showed no or poor response to various therapies, including plasmapheresis, corticosteroid, and tacrolimus. The patient was then treated with intravenous immunoglobulin (IVIG), and showed a good response that persisted over 20 months. The outcome of this case suggests that IVIG treatment may be an effective therapeutic option for anti-MuSK antibody-positive MG, with a potentially long-term effect.
Document Type: Research Article
Affiliations: 1: Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan 2: Department of Neurology, Toyama City Hospital, Toyama, Japan
Publication date: 2007-12-01